{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06290388",
            "orgStudyIdInfo": {
                "id": "23ME-01473-CLIN-001"
            },
            "organization": {
                "fullName": "23andMe, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of 23ME-01473 in Patients With Advanced Solid Malignancies",
            "officialTitle": "A Phase 1/2a, Multicenter, Open-label, Dose Escalation and Expansion Study of Intravenously Administered 23ME-01473 in Participants With Advanced Solid Malignancies",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-in-patients-with-advanced-solid-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-08",
            "studyFirstSubmitQcDate": "2024-02-26",
            "studyFirstPostDateStruct": {
                "date": "2024-03-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "23andMe, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard therapies.",
            "detailedDescription": "This study includes a dose escalation portion to determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) to evaluate the clinical activity of 23ME-01473 and further evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with solid malignancies."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor"
            ],
            "keywords": [
                "Cancer",
                "Phase 1",
                "Solid Tumor",
                "Oncology",
                "NK",
                "ULBP6",
                "Immunotherapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 82,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive escalating doses of 23ME-01473",
                    "interventionNames": [
                        "Drug: 23ME-01473"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "23ME-01473",
                    "description": "23Me-01473 given by intravenous infusion",
                    "armGroupLabels": [
                        "Phase 1"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1:Incidence and severity of dose-limiting toxicities (DLTs)",
                    "timeFrame": "First dose through 21 days post dose"
                },
                {
                    "measure": "Phase 1: Incidence and severity of adverse events (AEs)",
                    "timeFrame": "From Screening through 90 days post treatment"
                },
                {
                    "measure": "Phase 1 Incidence and severity of serious adverse events (SAEs)",
                    "timeFrame": "From Screening through 90 days post treatment"
                },
                {
                    "measure": "ORR based on investigator assessment against RECIST 1.1 criteria",
                    "timeFrame": "From baseline until disease progression (up to 5 years)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase 1: Prevalence and incidence of antidrug antibodies (ADA) to 23ME-01473",
                    "timeFrame": "From first dose up to 5 days post treatment discontinuation"
                },
                {
                    "measure": "Phase 1: Objective response rate (ORR)",
                    "description": "ORR based on investigator assessment against RECIST 1.1 criteria",
                    "timeFrame": "From baseline until disease progression (up to 5 years)"
                },
                {
                    "measure": "Duration of response (DoR)",
                    "description": "Duration of response based on investigator assessment against RECIST 1.1 criteria",
                    "timeFrame": "From baseline until disease progression (up to 5 years)"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "Disease control rate based on investigator assessment against RECIST 1.1 criteria",
                    "timeFrame": "From baseline until disease progression (up to 5 years)"
                },
                {
                    "measure": "Progression free survival (PFS)",
                    "description": "Progression free survival based on investigator assessment against RECIST 1.1 criteria",
                    "timeFrame": "From baseline until disease progression (up to 5 years)"
                },
                {
                    "measure": "Time of maximum serum concentration (Tmax) following a single dose of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose)]"
                },
                {
                    "measure": "Area under the concentration-time curve from zero to the last measurable concentration (AUClast) following a single dose of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose)]"
                },
                {
                    "measure": "Last measurable serum concentration (Clast) following a single dose of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose)]"
                },
                {
                    "measure": "Area under the concentration-time curve from zero extrapolated to infinity (AUCinf) following a single dose of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose)]"
                },
                {
                    "measure": "Terminal half-life (T1/2) following a single dose of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 1 (21 days, from Cycle 1 Day 1 predose to Cycle 2 Day 1 predose]"
                },
                {
                    "measure": "Maximum serum concentration (Cmax) following multiple doses of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)]"
                },
                {
                    "measure": "Time of maximum serum concentration (Tmax) following multiple doses of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)]"
                },
                {
                    "measure": "Area under the concentration-time curve from time zero to the end of the dosing interval (AUCtau) following multiple doses of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)]"
                },
                {
                    "measure": "Serum concentration at the end of the dosing interval (Ctau) following multiple doses of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)]"
                },
                {
                    "measure": "Terminal half-life (T1/2) following multiple doses of 23ME-01473",
                    "timeFrame": "[Time Frame: Cycle 4 (21 days, from Cycle 4 Day 1 predose to Cycle 5 Day 1 predose)]"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Phase 1: Adults \u2265 18 years of age\n2. Phase 1: Histologically-diagnosed locally advanced (unresectable), or metastatic carcinoma or sarcoma that has progressed after standard therapy for the specific tumor type.\n3. Adults 18+: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n4. Life expectancy \u2265 12 weeks\n5. Phase 1: Participants with evaluable disease are eligible regardless of tumor type, RECIST 1.1 can be used to assess disease progression.\n\nExclusion Criteria:\n\n1. Females who are pregnant (positive serum pregnancy test within 7 days prior to study drug administration) or breastfeeding.\n2. Immune-Related Medical History\n\n   1. Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years\n   2. Receipt of systemic immunosuppressive therapy (e.g. steroids) within 4 weeks prior to the start of study drug administration\n   3. History of idiopathic pulmonary fibrosis, interstitial lung disease, organizing pneumonia, non-infectious pneumonia that required steroids, or evidence of active, non-infectious pneumonitis\n   4. History of Grade \u2265 3 immune-mediated toxicity\n3. Prior allogeneic or autologous bone marrow transplant, or other solid organ transplant\n4. History of a positive test for:\n\n   1. Hepatitis C virus (HCV) infection, except for those who have completed curative therapy for HCV and have undetectable HCV RNA\n   2. Hepatitis B virus (HBV) infection, except for those who are receiving treatment with HBV-active nucleos(t)ide antiviral therapy at the time of study entry and have undetectable HBV DNA\n   3. Human Immunodeficiency Virus (HIV) infection, except those who meet the following criteria: CD4+ T cells \u2265 350 cells/\u03bcL, no history of Acquired Immunodeficiency Syndrome (AIDS)-defining opportunistic infections, HIV RNA \\< 50 copies/mL, and on a stable antiretroviral regimen for at least 3 months\n5. Prior anticancer therapy, including chemotherapy, targeted therapy, biological therapy or immune-checkpoint inhibitors within 4 weeks or 5 drug half-lives (whichever is shorter)\n6. History of another malignancy in the previous 2 years, unless cured by surgery alone and continuously disease free.\n7. Uncontrolled or symptomatic CNS (central nervous system) metastases and/or carcinomatous meningitis\n8. Recent history (within 6 months) of serious cardiovascular disease",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "110 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Inquiry",
                    "role": "CONTACT",
                    "phone": "650-963-8997",
                    "email": "studyinquiry@23andme.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jennifer Low, M.D,Ph.D",
                    "affiliation": "23andMe, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "START Midwest",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "Oregon Health & Science University",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "START Center for Cancer Care",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}